SciClone Pharmaceuticals (SCLN +30.7%) posted better-than-expected Q4 results, helped by a...

|About: SciClone Pharmaceuticals, Inc. (SCLN)|By:, SA News Editor

SciClone Pharmaceuticals (SCLN +30.7%) posted better-than-expected Q4 results, helped by a widened product portfolio boosted by its NovaMed acquisition and growth in sales of its key drug Zadaxin, and raised its 2012 forecast to EPS of $0.72-$0.78 on revenue of $165M-$170M vs. estimates of $0.43 on revenue of $168M.